NCT02203461 - Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Insulin Resistance

Interventions

DRUG

Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat

STRIBILD® QD, d1-14

DRUG

Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir

Truvada®/ Kaletra® 200/50 mg QD, d1-14

DRUG

Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir

Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14

Trial Locations (1)

University Hospital Klinikum rechts der Isar (TUM), Munich